Human Immunology News 5.42 October 24, 2017 | |
| |
TOP STORYGroup Uses Organoid to Explain Immune Cells’ Rapid Response Using a tool developed in the lab of Ankur Singh, Assistant Professor in the schools of mechanical and biomedical engineering, Singh and Dr. Ari Melnick report a method for uncovering the underlying mechanism that generates B cell proliferation. [Press release from Weill Cornell Medicine discussing online prepublication in Nature Communications] Press Release | Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)To characterize the complex interactions between graphene and immune cells, investigators proposed an integrative analytical pipeline encompassing the evaluation of molecular and cellular parameters. They used single-cell mass cytometry to dissect the effects of graphene oxide (GO) and GO functionalized with amino groups on 15 immune cell populations, interrogating 30 markers at the single-cell level. [Nat Commun] Full Article Hypoxia-Induced PD-L1/PD-1 Crosstalk Impairs T-Cell Function in Sleep Apnea Researchers studied the expression of programmed cell death (PD)-1 receptor and its ligand (PD-L1) on immune cells from patients with obstructive sleep apnea, and its consequences on immune-suppressing activity. They report that PD-L1 was overexpressed on monocytes and PD-1 was overexpressed on CD8+ T-cells in a severity-dependent manner. [Eur Respir J] Abstract The authors investigated the impact of targeting autophagy gene Beclin1 (BECN1) on the infiltration of natural killer (NK) cells into melanomas. They showed that, in addition to inhibiting tumor growth, targeting BECN1 increased the infiltration of functional NK cells into melanoma tumors. [Proc Natl Acad Sci USA] Full Article Researchers studied whether an antigen-specific mechanism of resistance to androgen-deprivation therapy (overexpression of the AR) may result in enhanced AR-specific T-cell immune recognition, and whether this might be strategically combined with an antitumor vaccine targeting the AR. Androgen deprivation increased AR expression in human and murine prostate tumor cells in vitro and in vivo. [Cancer Immunol Res] Abstract Scientists employed an unbiased cross-tissue transcriptomic approach to compare human group 3 innate lymphoid cells (ILC3s) from non-inflamed lymph nodes and spleen to their phenotypic counterparts in inflamed tonsils and from circulation. These analyses revealed that, in the absence of inflammation, lymphoid organ-residing ILC3s lack transcription of cytokines associated with classical ILC3 functions. [Cell Rep] Full Article | Graphical Abstract Investigators characterized semaphorin 4D (Sema4D) and the underlying mechanism contributing to the autoimmune features of bullous pemphigoid (BP). They found soluble Sema4D levels elevated and correlated with disease severity and activity in serum and blister fluids from patients with BP. [J Invest Dermatol] Abstract The authors defined a unique CD19hi B cell population existing in the periphery of systemic lupus erythematosus and pemphigus patients, as well as in human tonsils. CD19hi B cells could be induced in vitro after co-culturing fully activated CD4+ T cells with autologous B cells. [Sci Rep] Full Article In a Phase I randomized controlled clinical trial in HIV-1 negative volunteers, scientists investigated whether the site and mode of DNA vaccination influences the quality of the cellular immune responses. They adopted a strategy of concurrent immunization combining intramuscular injection with either intradermal or transcutaneous administration. [Sci Rep] Full Article Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSTargeting Immunosuppressive Adenosine in Cancer The authors describe the complex interplay of adenosine and adenosine receptors in the development of primary tumors and metastases and discuss the merits of targeting one or more components that compose the adenosinergic pathway. [Nat Rev Cancer] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
SCIENCE NEWSPhase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented Celgene Corporation announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 and 5 receptor modulator, in relapsing multiple sclerosis were accepted for presentation. [Press release from Celgene Corporation discussing research to be presented at the MSParis2017 – 7th Joint ECTRIMS-ACTRIMS Meeting, Paris] Press Release Xencor to Present Final Results from Phase II Study of XmAb®5871 in IgG4-Related Disease Xencor, Inc. announced that the final results from its open-label, Phase II study of XmAb®5871 in patients with IgG4-related disease will be presented in a late-breaking, oral presentation. [Press release from Xencor, Inc. discussing research to be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, San Diego] Press Release Aimmune Therapeutics to Present Data on Peanut Allergy Aimmune Therapeutics, Inc. announced that it will present data on peanut allergy during poster sessions at two upcoming medical meetings. [Press release from Aimmune Therapeutics, Inc. discussing research to be presented at the 2017 American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, Boston, and the 2017 European Academy of Allergy and Clinical Immunology’s Pediatric Allergy and Asthma Meeting (PAAM), London] Press Release AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data AbbVie announced that data from 38 abstracts of HUMIRA® and the company’s portfolio of investigational immunology medicines will be presented. [Press release from AbbVie Inc. discussing research to be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, San Diego] Press Release | |
| |
INDUSTRY NEWSInstitut Curie and Pierre Fabre Initiate a Novel Partnership in Immuno-Oncology Institut Curie and the Institut de Recherche Pierre Fabre will collaborate on new therapeutic strategies to advance cancer treatment for patients. The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models. [Institut de Recherche Pierre Fabre] Press Release IsoPlexis Corporation announced that it has received $1.8 million in grant funding from the National Cancer Institute’s Small Business Innovation Research Development Center to develop an automated assay platform and informatics suite that can be used in larger clinical trials to test CAR-T patient product potency and toxicity, pre-infusion, in order to help predict patient response and inform usage of these therapies. [IsoPlexis Corporation (PR Newswire Association LLC.)] Press Release Kite announced that the FDA has granted regular approval to Yescarta™, the first CAR T therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. [Gilead Sciences] Press Release | Editorial First ESMO Award for Immuno-Oncology Goes to Laurence Zitvogel The European Society for Medical Oncology (ESMO) has granted the newly established ESMO Award for Immuno-Oncology to Prof Laurence Zitvogel for her innovating and internationally recognised achievements in the field. [The European Society for Medical Oncology] Press Release | |
| |
POLICY NEWSIranian Scholar Sentenced to Death A judge in Tehran has ordered the death penalty for Iranian researcher Ahmadreza Djalali, according to his wife and diplomatic sources in Italy. Djalali is affiliated with the Karolinska Institute in Stockholm, Sweden, and the University of Eastern Piedmont in Novara, Italy. A resident of Sweden with his family, Djalali was arrested in April 2016 on an academic visit to Tehran and accused of “collaboration with a hostile government”. [Nature News] Editorial In Brazil, Researchers Struggle to Fend Off Deepening Budget Cuts With time and money running out, Brazilian scientists are turning up the pressure on the federal government to avoid a total collapse of the national science and technology funding system before the end of the year. Researchers delivered a petition with more than 82,000 signatures to congressional leaders in Brasília, demanding the reversal of deep budget cuts that have left research institutions struggling to pay even basic water and electricity bills. [ScienceInsider] Editorial
| |
EVENTSNEW World Vaccine Congress Washington 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Training Fellow – B Cell Immunology (The Francis Crick Institute) Research Technologist – Immunotherapy (STEMCELL Technologies Inc.) Scientist – Immunology (STEMCELL Technologies Inc.) Scientist – Immune Oncology (Dana-Farber Cancer Institute) Postdoctoral Researcher – Immunology (University of Luxembourg) Postdoctoral Fellowship – Tumor Immunology (UT Southwestern Medical Center) Postdoctoral Training Fellow – Immune Mechanisms (The Francis Crick Institute) Postdoctoral Fellow – Immunology (University of Rochester Medical Center) Postdoctoral Researcher – Development of Immune System (Lund University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|